Advertise | About Us | Contact Us

Interviews

Experts from pharma industry share their opinions and viewpoints on important issues relating to new trends, technologies, management insights and strategies in this section.

Bioquell Asia Pacific,

Green Shoots of Growth

Managing Director

Bioquell Asia Pacific, based in Singapore, in April 2009 to be the regional office for our activities in Asia and Australasia. I am responsible for the development of our business throughout the region and for the success and profitability of our activities. We provide equipment and services for environmental bio-decontamination across the pharmaceutical therapeutic development

GE Healthcare

Peter Ehrenheim

President & CEO

"Our current business focus and strengths are in the areas of bioprocessing, proteins, cellular analysis, cell handling and tools for cell therapy. Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide. We are particularly excited about the sample collection and storage opportunity with the FTA product line.We have a strong footprint in Asia and Japan and with access to this, the team at Whatman will be able to grow its global business."

Life Sciences - Clinical, TNT Asia

Lim Bee Koong

Director

"Clinical trials have very detailed and precise processes and the logistical elements of these processes are critical. Recent revisions to the pharmaceutical industry's regulatory laws as well as improved patent laws in countries such as Japan, China and India, have led to the burgeoning clinical trials market in Asia."

Accelovance China

Ken Ren

President

"Asia has had a dramatic spike in interest for medical research, pharma advancement and global investment. China and India are emerging as leaders in clinical trials. They recruit patients faster, cheaper and are better than Europe, South America or the US because the economies are encouraging more research."

Datamonitor

Laura Harris

Analyst

" include the changing patent laws as countries aim to become more TRIPS compliant, with India updating its law recently and China in the process of doing so through the WTO. Increasing globalization of the generics market, with Indian companies becoming involved in Europe and the US and vice versa, will also provide an opportunity for generics companies."

Charles River - Next Level Viral Safety Testing

Sartorius - Intensified CAR-T Manufacturing

PDA Aseptic Manufacturing and Regulatory Science Symposium 2026